Skip to main content
Premium Trial:

Request an Annual Quote

Miraca to Promote MDxHealth's Prostate Cancer Test

NEW YORK (GenomeWeb) – MDxHealth today announced a deal with Miraca Life Sciences to promote MDxHealth's ConfirmMDx Prostate Cancer test.

"Through this strategic partnership with MDxHealth, we can now offer a well-validated epigenetic assay, which delivers new molecular insights on a patient's risk for undetected cancer, thereby enabling our clients make more informed decisions about the need for a repeat prostate biopsy," Miraca President and CEO Frank Basile said in a statement.

The firm provides pathology services in dermatology, hematology, gastroenterology, and urology.

ConfirmMDx is an epigenetic assay that helps urologists distinguish patients with true-negative biopsies from those at risk for occult cancer. MDxHealth inked a deal with American Pathology Partners in May to promote and co-market the test in the US.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.